Lindbrook Capital LLC Has $168,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lindbrook Capital LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 303 shares of the company’s stock after acquiring an additional 55 shares during the period. Lindbrook Capital LLC’s holdings in IDEXX Laboratories were worth $168,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Blair William & Co. IL boosted its position in IDEXX Laboratories by 0.7% during the third quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock worth $524,700,000 after purchasing an additional 7,812 shares during the period. Brown Advisory Inc. boosted its position in IDEXX Laboratories by 2.2% during the third quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock worth $507,725,000 after purchasing an additional 24,741 shares during the period. Morgan Stanley boosted its position in IDEXX Laboratories by 4.7% during the third quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock worth $465,482,000 after purchasing an additional 48,095 shares during the period. Northern Trust Corp boosted its position in IDEXX Laboratories by 7.7% during the third quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock worth $401,935,000 after purchasing an additional 65,891 shares during the period. Finally, Principal Financial Group Inc. boosted its position in IDEXX Laboratories by 1.4% during the third quarter. Principal Financial Group Inc. now owns 815,863 shares of the company’s stock worth $356,753,000 after purchasing an additional 11,315 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Barclays increased their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Finally, The Goldman Sachs Group increased their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $591.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares in the company, valued at $45,377,624.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock worth $24,871,960 over the last 90 days. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Up 3.0 %

IDXX opened at $493.80 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm’s fifty day moving average price is $535.07 and its two-hundred day moving average price is $510.61. The company has a market capitalization of $41.01 billion, a P/E ratio of 49.04, a P/E/G ratio of 3.69 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same quarter in the previous year, the company earned $2.05 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.